Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer

Trial Profile

Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Pimasertib (Primary) ; Voxtalisib (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Feb 2017 Planned End Date changed from 1 May 2016 to 1 Nov 2017.
    • 22 May 2016 This trial was suspended in Poland and completed in Italy according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top